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ABSTRACT
Objectives The increasing incidence of chronic liver 
disease (CLD) in the UK may be attributed to a rise in 
preventable risk factors, including hazardous alcohol 
use and type 2 diabetes. Transient elastography (TE) can 
rapidly stratify risk of CLD in primary care populations and 
provide an opportunity to raise patient awareness of risk 
factors.
This study explores patients’ experiences of TE screening 
in a primary care setting. In addition, patient awareness of 
CLD risk is explored.
Study design and setting This study used a qualitative 
process evaluation of a community screening pathway 
for CLD (Nottingham, UK). Participants completed 
semistructured interviews, which were audio- recorded, 
transcribed verbatim and analysed thematically.
Participants Twenty adults were purposively recruited 
6 months to 2 years after TE screening. Inclusion criteria 
included (1) hazardous alcohol use, (2) type 2 diabetes 
and/or (3) persistently elevated liver enzymes without 
known cause.
Results Undergoing TE in primary care was seen as 
acceptable to most participants. Hazardous alcohol 
use was identified as the primary cause of CLD; no 
participants were aware of metabolic risk factors. TE 
improved understanding of personal risk factors and 
prompted contemplation of lifestyle changes across all TE 
stratifications. However, participants’ perceptions of risk 
were altered by the healthcare providers’ communication 
of TE scores.
Conclusions High acceptability of TE, regardless of 
the risk factor, provides strong support for inclusion of 
TE stratification in primary care. Findings highlight the 
positive impact of receiving TE on risk awareness. Future 
clinical iterations should improve the structure and 
communication of TE results to patients.
INTRODUCTION
Chronic liver disease (CLD) is the third most 
common cause of premature death in the 
UK, with mortality rates increasing by 400% 
since 1970.1 The rising incidence of CLD and 
the associated increase in mortality are driven 
by a rise in risk factors, such as hazardous 
alcohol use and type 2 diabetes, and are there-
fore considered preventable.2 3 However, the 
largely asymptomatic nature of CLD means 
initial detection of the disease predominantly 
occurs following hospitalisation with decom-
pensation, resulting in significantly impaired 
prognosis.4
Traditional approaches to the identification 
of CLD in primary care settings demonstrate 
poor sensitivity.5 In a community popula-
tion, abnormal liver enzymes were observed 
in approximately one- fifth of patients tested 
over a 5- year period.5 Despite this, detection 
of significant liver disease was remarkably 
low, occurring in only 1.14% of the sample.5 
Conversely, normal liver enzyme results do not 
accurately exclude underlying CLD; approxi-
mately 88% of patients with non- alcoholic 
fatty liver disease (NAFLD) above the age of 
65 years present with normal liver enzymes.6 
To improve the accuracy of early liver disease 
detection, recent guidelines recommend 
the use of additional risk stratification tools, 
particularly in patients with a known history 
of harmful alcohol use or NAFLD.7
Novel risk stratification approaches, such 
as transient elastography (TE), enable rapid 
identification of CLD in those who may be 
unaware of their illness.8 TE provides an 
immediate numerical value for liver stiff-
ness, allowing feedback to patients regarding 
their risk of liver disease within the same 
Strengths and limitations of this study
 ► This study presents the first qualitative evaluation of 
experiences of patients undergoing transient elas-
tography screening in primary care for non- viral liver 
disease.
 ► Purposive sampling allowed for representation of 
varied general practitioner locations and chronic liv-
er disease risk factors/diagnoses.
 ► Limited ethnic diversity in the sample potentially lim-
its generalisability to non- white British populations.
 ► The interviewer was involved in a larger community 
study of the screening pathway, which may have in-
advertently impacted the findings.
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appointment. Furthermore, the non- invasive nature 
of TE allows for rapid risk stratification that is readily 
deliverable in community settings.9 The Nottingham 
Community Liver Study was a large feasibility study that 
embedded portable TE devices (Fibroscan; EchoSens, 
Paris, France) into two general practitioner (GP) prac-
tices in the Rushcliffe borough of Nottingham, UK. The 
primary objective was to assess whether inclusion of TE 
as a risk stratification tool could improve early identifica-
tion of CLD. The combined patient population of both 
practices was 12 368, of whom 10% had type 2 diabetes or 
harmful alcohol use as a risk factor for CLD. TE screening 
of patients with these risk factors led to a 140% increase 
in diagnosis of cirrhosis, despite 90.9% of the patients 
with cirrhosis having normal liver enzymes.9
Integration of TE into primary care settings has allowed 
for successful identification of previously undetected 
CLD. However, before further implementation, it is 
important to assess the acceptability of this intervention 
to patients, including any barriers or enablers to uptake. 
This study presents a qualitative process evaluation of 
the Nottingham Community Liver Study, exploring the 
impact of undergoing TE in a primary care setting. We 
sought to understand patients’ experiences of the delivery 
and process of TE screening for CLD and the broader 
impact of TE screening on patient risk awareness.
METHODS
Study design and setting
This study was a qualitative process evaluation that used 
semistructured interviews to explore participants’ experi-
ences of CLD screening in primary care. Participants were 
purposively sampled from a large cohort of patients who 
underwent stratification of CLD in the community using 
a portable TE device (Fibroscan; EchoSens) as part of the 
Nottingham Community Liver Study (Nottingham, UK). 
A detailed description of this study and the recruitment 
processes has been published previously.9 Briefly, patients 
with defined risk factors for development of CLD were 
identified through electronic medical records and invited 
by their GPs to attend a liver assessment at their GP prac-
tice. Risk factors included any of (1) hazardous alcohol 
intake (defined as (i) >14 units per week for women and 
>21 units per week for men, (ii) and/or presence of alcohol 
misuse READ code, (iii) and/or Alcohol Use Disorders 
Identification Test score >8), or (2) type 2 diabetes, or 
(3) persistently raised liver enzymes without known cause. 
Patients were excluded if they showed evidence of hepatic 
fibrosis, cirrhosis or metastatic malignancy from previous 
investigation; contraindications existed for performing 
TE (eg, pregnancy, pacemakers); or severe cognitive 
impairment prevented consent.9 10 Before undergoing 
TE, patients were provided with information about the 
TE procedure. Following TE, all patients received lifestyle 
advice from the nursing staff and a British Liver Trust 
‘Looking After Your Liver’ leaflet, regardless of the TE 
result or risk factor.
To adequately represent those undergoing TE, the 
sampling strata for invitation for interview were (1) GP 
surgery location (suburban vs inner city), (2) CLD risk 
factor (hazardous alcohol use or type 2 diabetes) and (3) 
diagnosis assigned after community liver disease strat-
ification (normal liver stiffness vs liver fibrosis vs liver 
cirrhosis). Patients were excluded from interview selec-
tion if they were unable to communicate in English. 
Written consent was obtained following discussion with a 
trained research nurse.
Data collection and interview procedure
Interview questions were predominantly open- ended, 
with probes used where necessary to expand on partici-
pant responses. Both positive and negative views of the 
intervention were explored. The interview guide (online 
supplemental appendix 1) was reviewed by an indepen-
dent qualitative researcher (MB). The guide was piloted 
with a trained research nurse and the initial three partic-
ipants for testing and refinement. Only minor amend-
ments were made following the pilot, meaning the initial 
three participants were included in the analysis.
Face- to- face interviews were conducted over a 6- month 
period (by DH) with patients who had attended a TE 
assessment 6 months to 2 years before data collection. 
Interviews took place either in the participant’s home 
(n=14) or in an interview room at a tertiary care centre 
(n=6) (participant choice). Participants were notified 
that their interview responses would be anonymised. 
Interviews continued until data saturation was reached. 
Interviews were digitally audio- recorded and transcribed 
verbatim by a specialist transcription company.
Data analysis
Data were analysed thematically using an inductive 
approach.11 During the first phase of analysis, DH 
conducted a preliminary scan of the data, allowing 
generation of initial codes for data extracts. The anal-
ysis was then refocussed to sort and group the codes 
into analytical categories or ‘themes’. A ‘constant 
comparative’ method was used to compare individual 
data items with the rest of the data, ensuring that the 
preliminary themes retained importance with additional 
interviews.12 To ensure reliability of the coding system, 
MB independently coded and compared five interview 
transcripts.
During the second phase, themes were refined to 
ensure data cohered together meaningfully, with themes 
being clear and distinct. Themes were reorganised and 
collapsed as required. Finally, a detailed analysis was 
conducted for each theme, and data excerpts were identi-
fied to illustrate the final themes. All coding was checked 
by an independent researcher (MB) to ensure validity. 
NVivo V.11 (QSR International, Melbourne, Australia) 
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Patient and public involvement
Patients and members of the public were not involved in 




In total, 28 participants were invited for the interview. 
Eight declined participation, of whom seven declined due 
to time limitations and one could not remember under-
going TE. The remaining 20 participants completed 
the interview (mean length of the interview was 27.6 
min; SD=7.6; range, 16–46 min). The mean age of the 
participants was 57.9 years (SD=9.3; range, 40–71 years), 
and 12 participants (60%) were men. Participants were 
adequately distributed across the sampling strata (see 
table 1).
Thematic analysis
Analysis of the interviews revealed three main themes and 
two corresponding subthemes. Subthemes detail general 
acceptability, comprehension and impact of receiving TE 
results. Participant awareness of their risk of CLD before 
and after TE was also explored. The presenting risk 
factor and TE stratification are provided for each quoted 
participant.
Liver disease risk awareness
Participants discussed the impact that the risk stratifica-
tion pathway had on their own risk awareness. Before 
undergoing TE in primary care, participant knowledge of 
CLD risk factors was relatively limited. Hazardous alcohol 
use was recognised to be an important cause of CLD by all 
bar one of the participants. This knowledge was acquired 
from a number of sources, including media reports on 
the risks of alcohol and personal experiences of hepatic 
cirrhosis in close family or friends. Participants endorsed 
strong knowledge of the symptoms occurring in decom-
pensated liver disease and attributed these symptoms to 
excessive alcohol consumption. The term ‘alcoholic’ was 
commonly used to describe the origins of these symptoms:
I used to work with a bloke, he was an alcoholic, plain 
and simple. He was taken into hospital numerous 
times because of his liver packing up, he was down to 
10ml of liquid in a day at one point, that’s how ill he 
was, where he had to pack up drinking totally or die. 
(Participant 16, type 2 diabetes, liver fibrosis)
Despite consistent knowledge of alcohol use as a risk 
factor for CLD, awareness of personal risk of CLD in 
patients with hazardous alcohol use was variable. Oppor-
tunistic intervention by GPs generated awareness of 
multiple participants’ hazardous levels of alcohol use and 
led to a subsequent liver scan referral. However, several 
participants described that their alcohol intake was in 
keeping with their social group and endorsed feeling 
surprised when notified that their alcohol consumption 
level was considered to be hazardous and a risk factor for 
CLD.
Before TE, only one participant was aware that obesity 
could lead to CLD, and none of the participants were 
aware that type 2 diabetes was a risk factor. Subsequent to 
risk stratification, most participants reported an increased 
awareness of their personal risk factor for CLD, regardless 
of the TE result. In participants with hazardous alcohol 
use, this was acknowledgement that their personal alcohol 
consumption was hazardous, whereas for participants 
with type 2 diabetes it was learning that type 2 diabetes 
and obesity are risk factors for progressive CLD:
It was not something that ever crossed my mind, that 
diabetes could give you any serious problems with 
your liver or kidneys or anything. That was all very 
new to me, when they asked me to do the study, to 
go for the scan. (Participant 6, type 2 diabetes, liver 
cirrhosis)
Experience of stratification pathway
Acceptability and understanding of screening
Motivation to attend the TE appointment was driven by 
both medical and emotional factors. Participants with 
hazardous alcohol use were not routinely part of a medical 
programme (ie, diabetes management) prior to this 
study. Therefore, the invitation to undergo TE was unex-
pected and generated both surprise and anxiety in some 
individuals. However, in interviewed participants, this did 
not appear to preclude attendance for the TE appoint-
ment. Several participants discussed being accustomed 




  Male 12 (60)
  Female 8 (40)
GP location
  Inner city 12 (60)
  Suburban 8 (40)
CLD risk factor
  Alcohol 8 (40)
  Type 2 diabetes 12 (60)
TE result*
  Abnormal—cirrhosis 6 (30)
  Abnormal—fibrosis 7 (35)
  Normal 7 (35)
*TE result refers to diagnosis assigned on the basis of TE 
(FibroScan) reading of liver stiffness and subsequent confirmatory 
tests for abnormal scan to determine whether cirrhosis was 
present. Normal TE result, <8 kPa; Abnormal—fibrosis result, 8–15 
kPa; Abnormal—cirrhosis result, >15 kPa.
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to screening procedures as part of their routine diabetes 
care and were happy to attend on the recommendation 
of the GP team alone. Other participants endorsed a 
desire to attend the TE scan to enable the early detec-
tion of a liver problem before it resulted in any significant 
symptoms:
I was okay because I wanted things finding out, if there 
was anything, you know, wrong with me. (Participant 
2, type 2 diabetes, liver cirrhosis)
The majority of participants recalled a basic under-
standing of the TE device derived from either a leaflet 
provided prior to the appointment or the explanation 
provided by the nurses during the appointment. Several 
participants accurately described the use of TE to explore 
scarring in the liver and used terminologies such as 
‘rigidity’, ‘hardness’ or ‘stiffness’:
The two nurses, they were very good and they ex-
plained how it worked and what happens to the test, 
so they explained it well, what it was measuring; it was 
the density of the liver, like an ultrasound, so they ex-
plained all that and they were very good. (Participant 
20, hazardous alcohol use, normal liver scan)
The process of being screened for CLD in a primary 
care setting was regarded as a positive experience by 
most. Many participants reported that being reviewed at 
their GP practice, rather than in a hospital setting, was 
convenient and allowed attendance outside of working 
hours. One participant also felt that attendance rates for 
liver scans in the community would be improved due to 
this convenience. For most participants, the rapidity of 
the screening was seen as surprising, while the TE scan 
itself was described as painless:
It was all done in 20 minutes over and done with 
and it was not a problem at all, it was probably the 
easiest scan I’ve ever had, for anything! When they 
say ‘it’s done’, you think ‘already?’. ‘It takes a bit lon-
ger than this to have an appointment with the GP’. 
(Participant 16, type 2 diabetes, liver fibrosis)
One participant described the scan as an uncomfort-
able procedure, although later described the process of 
having a liver biopsy as comparatively more painful. Nega-
tive feedback was also expressed by one participant for 
whom it was not possible to obtain a valid liver assessment 
in the community. Although the participant felt that the 
concept of community liver scanning was a good idea, he 
did not feel that the process itself was well executed. This 
participant was subsequently referred to secondary care 
for TE screening.
Comprehension of results
Participants’ recall of their numerical liver stiffness value 
was inconsistent. Several participants did not remember 
receiving a numerical result, whereas approximately half 
of the participants interviewed were still able to recall 
their exact liver stiffness measurement. Participants’ 
preference for the format of their liver stiffness result also 
varied. Some participants felt that simple categorisation 
of their scan result as normal or abnormal was informative 
enough. Other participants preferred a numerical value 
as the result felt more personalised and provided a base-
line for comparison in case further scans were required:
The terms ‘satisfactory’, ‘normal’, ‘good’, ‘very good’, 
‘excellent’, they’re all subjective, they mean different 
things to different people but a score is a score, if you 
have a score of 6.1, it’s not 6.2 and neither is it 5.9, it’s 
a definite starting point. (Participant 5, type 2 diabe-
tes, normal liver scan)
Several participants felt able to use the numerical liver 
stiffness result to assess the severity of their liver disease. 
However, multiple participants described feeling uncer-
tain about how to interpret the severity of abnormal 
results as the possible ranges and severities of liver stiff-
ness results did not appear to be consistently discussed 
during the screening.
Impact of screening result
Most participants reported the expectation that liver 
abnormality would not be detected. This was derived 
from a number of factors, including a prior lack of knowl-
edge regarding their own risk factor for developing 
CLD, the absence of previous symptoms and in several 
participants previously normal liver function blood tests. 
Following delivery of the scan results, participants with 
normal liver stiffness described a sense of relief that a 
significant problem or additional comorbidity was not 
detected. Conversely, participants with elevated liver 
stiffness results commonly reported feeling surprised, 
shocked or anxious. For those diagnosed with cirrhosis, 
most expressed concern that their disease would prog-
ress quickly or result in their premature death. However, 
several participants expressed relief following diagnosis 
with cirrhosis rather than an underlying malignancy:
Everybody thinks there might be cancer there some-
times and it was just ‘oh it’s not a cancer, it’s that … 
in another five years or so!’ (Participant 19, type 2 
diabetes, liver cirrhosis)
Provider delivery of the scan result appeared to 
contribute to the impact of the result. Specifically, several 
participants with fibrosis felt that the abnormality of 
their TE results did not represent a significant health 
issue because of the message conveyed by the healthcare 
provider conducting the scan. This resulted from the 
perception that mild elevations did not warrant concern:
They told me that mine was above but not seri-
ous. That’s what they said it was. Nothing to worry 
about, it was above normal but ‘don’t worry about it’. 
(Participant 9, type 2 diabetes, liver fibrosis)
The CLD screening process provided multiple oppor-
tunities to raise participant awareness of their liver health 
and fostered contemplation of potential lifestyle changes. 
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Both hazardous alcohol users and participants with type 
2 diabetes receiving normal liver stiffness results reported 
immediate contemplation of lifestyle changes. Partici-
pants with elevated liver stiffness discussed the abnormal 
result, and subsequent advice from the nursing team and 
liver specialist, as the initiator of contemplation of life-
style changes. Several participants discussed that being 
told they had an abnormal liver scan was a ‘wake- up call’ 
and subsequently prompted them to consider changes 
that could be made to their lifestyle.
What was the trigger that got you thinking that you needed 
to do something?
Having an abnormal test, no doubt about that. I 
think we all like to think we’re perfect …! If there’s 
something wrong and you can do something about 
it, you’re daft if you don’t, that’s the way I look at it. 
(Participant 9, type 2 diabetes, liver fibrosis)
As a marker of acceptability, all participants were willing 
to undergo further CLD screening in primary care, with 
most reporting that an interval of 3–5 years for repeated 
TE scans would be reasonable. Participants with normal 
liver stiffness felt it would be important to repeat the 
liver scan to ensure that no new abnormality had devel-
oped. For participants with abnormal liver stiffness, the 
most important reasons for repeating the TE scan were 
to monitor for worsening of their CLD and to detect 
whether improvements in lifestyle had resulted in subse-
quent improvements in liver stiffness.
DISCUSSION
Summary
This study provides a qualitative evaluation of patients’ 
experiences with a primary care liver disease stratifica-
tion pathway. Specifically, the study provides insight into 
patients’ perceptions of TE screening and diagnosis in 
the community while exploring patient risk awareness. 
The resulting themes suggest that screening for risk of 
CLD in the community is acceptable to ‘at- risk’ patients. 
Most participants reported positive experiences of the 
screening process, highlighting the convenience of 
undergoing TE in a primary care setting, the speed of 
the appointment and the painless nature of the TE scan. 
Participants were willing to undergo a repeat TE scan in 
the future. For any screening programme, participant’s 
acceptance of the investigation is crucial; therefore, these 
findings add to the evidence that TE is a suitable method 
for risk stratification of CLD in primary care populations. 
While most participants reported knowledge of exces-
sive alcohol use as a risk factor, there was very limited 
awareness of the connection between diabetes and CLD. 
Importantly, undergoing TE improved risk awareness in 
all participants and prompted contemplation of lifestyle 
changes in most.
Comparison with existing literature
The utility and acceptability of TE as a risk stratification 
tool have been well documented, including populations 
with hepatitis C.10 13 14 This study builds on these findings 
by demonstrating the acceptability of TE to patients with 
non- viral risk factors, allowing effective risk stratification 
in patients with both hazardous alcohol use and meta-
bolic conditions.
Within this study, many hazardous alcohol users were 
unaware that their alcohol use reached hazardous levels 
before referral for TE. This corroborates previous quali-
tative work demonstrating that midlife drinking is heavily 
governed by social norms and an association between 
problem drinking and the inability to fulfil basic family 
and work responsibilities.15 16 A lack of patient knowledge 
may also result from healthcare providers’ limited under-
standing about problematic drinking behaviours. In their 
qualitative interview study of healthcare professionals 
who deliver brief intervention advice for alcohol, Rapley 
and colleagues demonstrated that providers were uncer-
tain of what constituted ‘at- risk’ alcohol intake, resulting 
in reduced confidence to provide alcohol consumption 
advice.17 A lack of risk awareness did not, however, seem 
to preclude uptake of the TE scan in those with hazardous 
alcohol use.
Strikingly, knowledge that obesity and type 2 diabetes 
are risk factors for CLD was uncommon even in patients 
with these risk factors. Participants with type 2 diabetes 
frequently reported surprise at receiving an invitation to 
undergo TE screening. Wieland and colleagues explored 
awareness of NAFLD risk in individuals presenting to an 
endocrinology clinic. Of those with significant risk factors 
(ie, overweight/obese and insulin- resistant), only 24% 
were aware of their risk of developing NAFLD.18 Previous 
studies have also described a lack of NALFD- specific 
knowledge among primary care providers, leading to 
the absence of CLD education during routine diabetes 
consultations and support courses.19 20 In this study, TE 
screening provided an opportunity to raise awareness of 
patients’ risk of developing CLD. However, education 
courses and public health interventions enhancing knowl-
edge of CLD risk factors in both patients and healthcare 
professionals are warranted.
Implications for practice
The results highlighted several areas within the pathway 
that may require modification prior to further implemen-
tation. Negative feedback about the stratification pathway 
related to failed liver stiffness acquisition. Although body 
mass index (BMI) was not formally assessed as part of the 
qualitative process evaluation, it is worth considering the 
impact of BMI on stiffness acquisition. In the Community 
Liver Study, 97% of patients were successfully stratified 
using a medium- sized probe in primary care.9 However, 
patients with a BMI ≥35 kg/m2 were referred to secondary 
care to undergo TE with an extra- large (XL) probe. 
Recent data suggest that use of an XL- sized probe on a 
portable TE device significantly increases the number of 
valid and reliable readings in patients with a raised BMI.21 
Given the increasing rates of overweight and obesity in 
primary care settings, a community stratification pathway 
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should have both medium and XL probe sizes available 
for use to improve successful liver stiffness acquisition 
rates. Given that patients’ experiences of undergoing 
TE in the community will likely be impacted by BMI, 
future studies should address the subjective experience 
of patients with a range of BMIs.
Previous behaviour change studies have also demon-
strated that numerical biomarker feedback increases 
lifestyle advice uptake by demonstrating physical damage 
that patients have caused to themselves.22 23 Within this 
study, the utility of the numerical liver stiffness value 
was variable. Some patients struggled to comprehend 
the context or scaling of their result, whereas others 
found the specific liver stiffness unit useful as a base-
line or comparison point. Feedback to patients could be 
improved by ensuring a clear and structured explana-
tion of how the result relates to the degree of liver scar-
ring, with the provision of a more comprehensive scale 
to anchor the feedback. It also seemed that the percep-
tion of risk of developing CLD varied as a result of the 
way in which these liver stiffness values were explained. 
Specifically, while significantly abnormal results gener-
ated short- term shock and anxiety, less severe or normal 
results were perceived as ‘nothing to worry about’. Given 
that all patients were referred for liver assessment based 
on a compilation of risk factors, the prospective risk of 
developing CLD should be clearly conveyed to patients. 
Providers may therefore benefit from additional training 
and guidance in the delivery of TE results to patients.
Strengths and limitations
This study has several strengths. First, participants were 
invited to be interviewed 6 months to 2 years following 
their TE appointment, allowing assessment of long- term 
perceptions about the process while minimising the 
likelihood that details of the pathway were forgotten. In 
addition, participants were purposively sampled from 
inner city and suburban locations, with different CLD 
risk factors and CLD diagnoses. It is believed that the use 
of this sampling technique may allow transferability to 
similar primary care settings within the UK.
Several limitations to the study have also been noted. 
It is possible that engagement with other liver disease 
services during the period between TE and interview 
may have impacted participant recall. Those diagnosed 
with cirrhosis will have been referred to secondary care 
hepatology services, with the remainder returned to 
primary care. However, we noted no differences in the 
identified main themes between risk groups, just in the 
subtheme relating to immediate response to the result. 
In addition, the characteristics of the individuals who 
declined to participate were not stored following their 
decline. As a result, it is possible that those who chose 
not to participate were inherently different from those 
who participated. As with most qualitative data collection, 
the interviewer’s presence may have impacted participant 
responses. Importantly, the interviewer (DH) was involved 
in the larger community study and had previously met 
those participants with elevated liver stiffness (n=13). To 
minimise response bias, participants were notified that all 
interview transcripts would be anonymised. The reliability 
and validity of data collection and analysis were also opti-
mised by including an independent researcher (MB) 
in the development of the interview guide and through 
investigator triangulation during transcript coding. While 
attempts were made to represent broader community 
populations, two sampling limitations are noted. First, 
non- English- speaking patients were excluded from the 
interviews. Liver disease prevalence varies widely among 
different ethnic groups, particularly regarding aetiology 
and risk of hospitalisation and mortality.24 25 Our findings 
may therefore not generalise to ethnically diverse popu-
lations. Furthermore, the age range of interviewees was 
relatively narrow (40–71 years). However, this reflects 
the decades where people are most at risk of developing 
CLD, with the average age of death from CLD being 59 
years in the UK.26
CONCLUSION
In summary, undergoing TE to screen for CLD in the 
community was acceptable to most participants and 
resulted in greater awareness of liver disease risk, regard-
less of the risk factor. The findings suggest benefits of 
population- based liver disease screening in addition to 
merely earlier diagnoses. Future interventions should 
target improved awareness of liver disease risk factors in 
both patients and providers.
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APPENDIX 1: Interview Guide 
 
Prior knowledge of liver disease/views of health: 
- Before being contacted about the liver tests, how would you describe your 
health?  
- Can you tell me what you knew about the risks of excessive alcohol 
consumption/diabetes? (probe to ask about liver disease if not mentioned by 
participant) 
- Ask about patient’s own risk – alcohol consumption/diabetes control pre-
scan? 
- Had you intended to make any attempts to improve your lifestyle/health prior 
to the liver tests? (probe to ask why/why no prior attempts). If so, what did you 
do? What triggered the previous lifestyle changes? 
- Who contacted you about having tests to check your liver function? 
- What information did you receive about the scan before having it? 
- Did you understand why you were contacted to have the scan done? 




Scan experience and results: 
     -    When did you have the liver scan done? 
- Please take me through what you remember about having the liver scan 
done? 
- How would you describe your feelings about having this test done? 
- Did you understand what the scan was looking for?  
- Can you tell me about your results from the liver scan? Probe around who 
discussed the results and were they explained clearly? 
- Have you remembered the number result (liver stiffness) that the scan 
produced? If so, did this result mean anything to you? 
- How did the scan results make you feel at the time? 
 
 
                      
Current Health Beliefs: 
- Did having the liver tests have an impact on how you view your health? 
- Since having the tests, is there anything you have learned about liver 
disease? 
- To what extent have your health beliefs changed since having the liver scan? 
- To what extent has information from the doctors or nurses had a role in 
changing how you view your health? 
- Has the scan prompted you to make lifestyle changes? 
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